NO994967L - Gen-avleveringsvehikkel som uttrykker de apoptoseinduserende proteiner VP2 og/eller apoptin - Google Patents

Gen-avleveringsvehikkel som uttrykker de apoptoseinduserende proteiner VP2 og/eller apoptin

Info

Publication number
NO994967L
NO994967L NO994967A NO994967A NO994967L NO 994967 L NO994967 L NO 994967L NO 994967 A NO994967 A NO 994967A NO 994967 A NO994967 A NO 994967A NO 994967 L NO994967 L NO 994967L
Authority
NO
Norway
Prior art keywords
apoptosis
gene delivery
delivery vehicles
apoptin
relates
Prior art date
Application number
NO994967A
Other languages
English (en)
Norwegian (no)
Other versions
NO994967D0 (no
Inventor
Matheus Hubertus Mari Noteborn
Alexandra Maria Pietersen
Original Assignee
Leadd Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP97201121A external-priority patent/EP0872552A1/de
Application filed by Leadd Bv filed Critical Leadd Bv
Publication of NO994967D0 publication Critical patent/NO994967D0/no
Publication of NO994967L publication Critical patent/NO994967L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO994967A 1997-04-15 1999-10-12 Gen-avleveringsvehikkel som uttrykker de apoptoseinduserende proteiner VP2 og/eller apoptin NO994967L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97201121A EP0872552A1 (de) 1997-04-15 1997-04-15 Genabgabe-Vehikel die das Apoptosis VP2 induzierendes Protein und/oder Apoptin exprimiert
EP97203595A EP0878546A1 (de) 1997-04-15 1997-11-18 Genabgabe-Vehikel die das Apoptosis VP2 inducierendes Protein, und/oder Apoptin exprimiert
PCT/NL1998/000213 WO1998046760A1 (en) 1997-04-15 1998-04-15 A gene delivery vehicle expressing the apoptosis-inducing proteins vp2 and/or apoptin

Publications (2)

Publication Number Publication Date
NO994967D0 NO994967D0 (no) 1999-10-12
NO994967L true NO994967L (no) 1999-12-15

Family

ID=26146368

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994967A NO994967L (no) 1997-04-15 1999-10-12 Gen-avleveringsvehikkel som uttrykker de apoptoseinduserende proteiner VP2 og/eller apoptin

Country Status (17)

Country Link
EP (2) EP0878546A1 (de)
JP (1) JP2001521387A (de)
KR (1) KR100528755B1 (de)
AT (1) ATE275200T1 (de)
AU (1) AU750162B2 (de)
BR (1) BR9808542A (de)
CA (1) CA2286165C (de)
CZ (1) CZ299963B6 (de)
DE (1) DE69825978T2 (de)
DK (1) DK0975764T3 (de)
ES (1) ES2227822T3 (de)
NO (1) NO994967L (de)
NZ (1) NZ500012A (de)
PL (1) PL196607B1 (de)
PT (1) PT975764E (de)
SK (1) SK285724B6 (de)
WO (1) WO1998046760A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL196605B1 (pl) 1997-08-12 2008-01-31 Leadd Bv Sposób oznaczania zdolności transformującej, sposób oznaczania predyspozycji do przekształcania się w komórkę nowotworową, sposób oznaczania predyspozycji do dziedziczenia rodzajów raka, sposób oznaczania mutacji genu i diagnostyczny zestaw testowy
DE60003632T2 (de) * 1999-01-11 2004-04-15 Leadd B.V. Verwendung von apoptose-induzierende mittel zur herstellung eines mittels zur behandlung von (auto)immunkrankheiten
AU2004233486B2 (en) * 1999-01-11 2007-09-13 Leadd B.V. Use of apoptosis inducing agents in the treatment of (auto)immune diseases
CA2383784A1 (en) * 1999-09-02 2001-03-08 Leadd B.V. Apoptin-associating protein
EP1081226A1 (de) * 1999-09-02 2001-03-07 Leadd B.V. Apoptin-bindendes Protein
WO2001042461A2 (en) 1999-12-10 2001-06-14 Leadd B.V. Apoptin-associating protein
EP1377667B1 (de) * 2001-03-30 2008-11-19 Leadd B.V. Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
KR100561985B1 (ko) 2004-07-03 2006-03-22 고려대학교 산학협력단 종양 특이적 아폽틴 발현 카세트 및 이를 포함하는아데노바이러스 발현 벡터
KR100877824B1 (ko) 2005-11-11 2009-01-12 한국생명공학연구원 Ｅ2ｅｐｆ ｕｃｐ-ｖｈｌ 상호작용 및 그 용도
CN109111527B (zh) * 2018-08-03 2022-03-15 沈阳金石生物制药有限公司 靶向特异性诱导肿瘤细胞凋亡的gip34-vp3融合蛋白及其制备方法和应用
CN109266714A (zh) * 2018-10-12 2019-01-25 广州医科大学 一种循环肿瘤细胞的检测方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9002008A (nl) * 1990-09-12 1992-04-01 Stichting Centr Diergeneeskund Recombinant dna en rna en daarvan afgeleide produkten.
NL9301272A (nl) * 1993-07-20 1995-02-16 Aesculaap Bv Chicken Anemia Virus mutanten en vaccins en toepassingen gebaseerd op de virale eiwitten VP1, VP2 en VP3 of daarvoor coderende sequenties van dat virus.
FR2732348B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Systeme d'expression conditionnel

Also Published As

Publication number Publication date
KR100528755B1 (ko) 2005-11-15
PL336312A1 (en) 2000-06-19
CZ299963B6 (cs) 2009-01-07
CZ349399A3 (cs) 2000-02-16
DE69825978D1 (de) 2004-10-07
PT975764E (pt) 2004-11-30
NZ500012A (en) 2001-04-27
DE69825978T2 (de) 2005-09-15
SK285724B6 (sk) 2007-07-06
NO994967D0 (no) 1999-10-12
PL196607B1 (pl) 2008-01-31
SK142899A3 (en) 2000-06-12
WO1998046760A1 (en) 1998-10-22
CA2286165C (en) 2009-02-03
KR20010006460A (ko) 2001-01-26
ATE275200T1 (de) 2004-09-15
EP0975764B1 (de) 2004-09-01
CA2286165A1 (en) 1998-10-22
DK0975764T3 (da) 2005-01-03
EP0975764A1 (de) 2000-02-02
ES2227822T3 (es) 2005-04-01
JP2001521387A (ja) 2001-11-06
EP0878546A1 (de) 1998-11-18
BR9808542A (pt) 2000-05-23
AU750162B2 (en) 2002-07-11
AU6856398A (en) 1998-11-11

Similar Documents

Publication Publication Date Title
Vile et al. The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider
NO994967D0 (no) Gen-avleveringsvehikkel som uttrykker de apoptoseinduserende proteiner VP2 og/eller apoptin
DK0797678T3 (da) Hybrid adenovirus-AAV-virus og fremgangsmåder til anvendelse af dette
PT797676E (pt) Vector adenoviral recombinante e metodos de utilizacao
NO20004631D0 (no) Forbindelser og fremgangsmÕter for terapi og diagnose av lungekreft
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
ATE520420T1 (de) Das telomelysin-gfp-gen enthaltendes rekombinantes virus
FI95472B (fi) Menetelmä ihmisen tuumorinekroositekijän valmistamiseksi ja sitä koodaava DNA
ES2061708T3 (es) Virus recombinante de la viruela de la gallina, vectores de expresion de proteinas heterologas y vacunas para aves de corral derivadas de este virus.
ATE229977T1 (de) Peptide mit antiproliferativen eigenschaften
AU5464000A (en) Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins
DE3585790D1 (de) Varicella-zoster-virus-dns-sequenzen, diese enthaltende vektoren und wirtzellen, uebereinstimmende polypeptide und diese enthaltende verbindungen.
CA2167578A1 (en) Chicken anemia virus mutants and vaccines and uses based on the viral proteins vp1, vp2 and vp3 or sequences of that virus coding therefor
EP1536006A4 (de) Krebsantigene und deren nutzung
DK1082423T3 (da) Cyclin E2-gener og -proteiner
ATE349225T1 (de) Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv
WO1999028461A3 (en) Methods and means for inducing apoptosis by interfering with bip-like proteins
DK498387D0 (da) Virus-dna-sekvens
NO950420L (no) Interferon endelse derav
ATE501255T1 (de) 84p2a9: prostata- und hodenspezifisches protein, das sehr stark bei prostatakrebs vorkommt
DK0817859T3 (da) Rekombinante DNA vektorer til Genterapi
NO20005321L (no) Vertskodet protein uttrykt i Mareks sykdoms (MDV) infiserte celler og antistoffer til dette
ATE210990T1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application